MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Bioequivalence of IVAX Warfarin Tablets and Coumadin Brand Warfarin Tablets in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: IVAX Warfarin
Drug: BMS Coumadin
First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
36
Registration Number
NCT02171494

Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Telmisartan
Drug: Losartan
Drug: Hydrochlorothiazide
First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
363
Registration Number
NCT02172586

Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 10773
Drug: Sitagliptin
First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT02172196

Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: dabigatran etexilate
Drug: quinidine
First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
42
Registration Number
NCT02171624

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: BIBW 2992
Drug: Docetaxel
First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
31
Registration Number
NCT02171741

Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Dabigatran high dose
Drug: Dabigatran low dose
First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT02171468

Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Tiotropium inhalation powder capsule
Drug: Ipratropium Bromide Metered Dose Inhaler
Drug: Placebo Metered Dose Inhaler
Drug: Placebo inhalation powder capsule
First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
215
Registration Number
NCT02172469

Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers

First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
42
Registration Number
NCT02171546

Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Dabigatran etexilate low
Drug: Dabigatran etexilate high
First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
28
Registration Number
NCT02171572

Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBW 2992 MA2 - single rising dose
First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT02171767
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy